were not demonstrated in the 13 haemodialysis (HD) subjects. Background. Erythropoietin (rHuEpo) therapy has been shown to improve sexual function in the male Conclusions. Male dialysis patients complaining of sexual dysfunction after correction of anaemia with dialysis population, with several studies suggesting a direct effect upon endocrine function, as well as correc-rHuEpo are characterized by higher levels of serum testosterone and SHBG, but not suppression of hypertion of anaemia. Nevertheless many male dialysis patients receiving rHuEpo continue to complain of prolactinaemia or hyperoestrogenism. Male PD subjects receiving rHuEpo also demonstrated increased sexual dysfunction. Methods. At a dedicated renal impotence clinic, 65 LH and FSH. male dialysis patients were screened for endocrine Key words: erythropoietin; sexual dysfunction; enddisturbances. Baseline serum sex hormones were comstage renal failure ( ESRF ); impotence; dialysis; pared between those receiving and not receiving testosterone; prolactin; sex hormone binding globulin rHuEpo, using either the two-sample t test or the (SHBG) Mann-Whitney U test, after assessing for normality. Results from four patients were excluded on account of either medications (antiemetic phenothiazines), hepatic dysfunction, or carcinomatosis.
performed prior to dialysis in the HD population and at the firm this in male dialysis patients [4, 5, 8, 9 ] . The influclinic visit in the CAPD and CCPD patients. Serum T, ence of rHuEpo on hormones affecting sexual function SHBG, LH, FSH, E2, PRL, total T4, TSH, and cortisol in this population thus remains disputed.
were measured by radioimmunoassay using commercially A renal impotence clinic was established at Leicester available assays. Data on SHBG was available on only 33 General Hospital in 1992, after a postal survey had patients (30 receiving CAPD or CCPD and 3 intermittent previously shown that 48.6% of the male dialysis HD). An index of free testosterone was estimated as the population had impotence difficulties requiring atten-ratio of T to SHBG. tion. Many patients were receiving rHuEpo therapy, Four patients were excluded from the assessment, as they and whilst an often repeated description was given of had other medical pathologies (carcinomatosis and hepatic dysfunction, n=2 ) or medications (antiemetic phenothiazimproved libido after its commencement, there was a ines, n=2) making a marked contribution.
continued difficulty to form normal penile erections.
Data are expressed either as mean±SEM or median
The routine clinical practice was to measure basal (range) . The distribution of the data was assessed by the endocrinological function and assess whether those Shapiro-Wilk W test for normality. Only age, Hb, total T4 patients who had not experienced correction of sexual and T were normally distributed. These were compared with dysfunction following rHuEpo therapy had character-the two-sample t test, whereas other groups were assessed istic hormonal differences from non-recipients. The using the Mann-Whitney U test, utilizing the software packpresent study describes the contrasting endocrinolog-age 'Minitab for Windows'. Correlations were analysed by ical profiles of male dialysis patients who were either Pearson's linear correlation coefficient, using ' Fig P for receiving rHuEpo or deemed not to require it, although Windows'. Statistical significance was accepted at P<0.05. all were complaining of sexual difficulties.
Results

Subjects and methods
Twenty-five male dialysis patients (41.0%) were receivSubjects ing rHuEpo therapy, their age and Hb being similar Over a 3-year period, 65 male dialysis patients complaining to the remainder ( Table 1) . There was a similar distriof sexual dysfunction were investigated. Forty-nine patients bution of the different modes of dialysis, with most were dialysed with continuous ambulatory peritoneal dialysis having CAPD or CCPD (76.0 vs 80.6%), and a minor-(CAPD), three received continuous cycling peritoneal dialysis ity intermittent HD ( 24.0 vs 19.4%). There was no (CCPD), and 13 underwent intermittent HD. There were no difference in plasma urea, total protein and albumin exclusion criteria for attendance to the clinic and the under- (Table 1 ) , but the rHuEpo recipients had a higher lying renal aetiologies of the study population were chronic median plasma creatinine level (P<0.02). The seven glomerulonephritis (n=14), diabetic nephropathy (n=13), predialysis subjects were older than the rHuEpo recipihypertensive nephropathy (n=8), adult polycystic kidney ents (P<0.01) and non-recipients (P=0.068); they also disease (n=6), chronic pyelonephritis (n=3), renovascular disease (n=3), Wegener's granulomatosis (n=3), uncertain demonstrated a higher mean haemoglobin (P<0.001) (n=8 ), and others (n=7).
and lower median creatinine (P<0.001).
A further seven male predialysis patients were also investiThe total duration of rHuEpo therapy was 0.85± gated. Their renal aetiologies were diabetic nephropathy 0.14 years with a mean weekly dose of 4920±510 (n=2), adult polycystic kidney disease (n=2), chronic glom-units. A strong positive correlation was demonstrated erulonephritis (n=1), renovascular disease (n=1), and between the total duration of rHuEpo and duration of previous acute tubular necrosis (n=1). dialysis (r=0.726, P<0.0001), and there was a trend toward longer duration of dialysis in the rHuEpo Methods recipients (P=0.075), but no difference in the duration of impotence ( Table 1 ). The duration of impotence A detailed medical history was taken at the first visit, and and the length of dialysis positively correlated in both note was made of the presence or absence, and duration, of groups (r=0.539, P<0.01 and r=0.542, P<0.002). ( Table 2 ). There emetics (n=2 ).
Routine blood investigations were haemoglobin ( Hb) was a trend toward higher E2 levels (P=0.095), but (normal range ( NR) 13.5-18 g/dl ), haematocrit (NR no difference was observed in LH, FSH and PRL 0.40-0.54 ), plasma urea ( NR 2.5-6.5 mmol/l ), creatinine ( Figure 1 ). The pre-dialysis subjects were not hyperoes-( NR 60-120 mmol/l ), protein ( NR 60-80 g/l ), and albumin trogenic or hyperprolactinaemic, unlike the dialysis ( 35-55 g/l ). The endocrinological screen comprised serum T patients ( Table 2) , and demonstrated decreased SHBG ( NR 9.4-37 nmol/l ), sex hormone binding globulin (SHBG) (P<0.05) and LH (P<0.05) compared to the rHuEpo ( NR 20-45 nmol/l ), luteinising hormone ( LH) ( NR recipients, as well as trend towards decreased serum T 54-142 nmol/l ), thyroid stimulating hormone ( TSH ) (NR 0.3-3.8 mu/l ) and cortisol (NR 138-690 nmol/l ). These were in those not requiring rHuEpo, but not in the rHuEpo Values are expressed as mean±SEM or median (range). 1vs rHuEpo recipients, P<0.01; vs rHuEpo non-recipients, P=0.068 (n.s.); 2vs rHuEpo recipients and non-recipients, P<0.001; 3vs rHuEpo recipients, P<0.05; vs rHuEpo non-recipients, P<0.01; 4vs rHuEpo recipients, P<0.02; 5vs rHuEpo non-recipients, P<0.05. recipients (r=0.217, p=0.297 and r=0.285, P=0.167 0.339, P=0.143), although Hb and serum cortisol were positively correlated (r=0.433, P<0.02). respectively). Duration of dialysis and E2 were positively correlated in the former subjects (r=0.515, The ages of the PD and HD subgroups were similar, but the HD patients had a longer duration of sexual P<0.002), while there appeared to be a trend in the rHuEpo recipients (r=0.377, P=0.069); however, dysfunction (P<0.05, Table 3 ). The duration of dialysis was shorter in the PD subjects who were not total duration of rHuEpo therapy and E2 did positively correlate (r=0.465, P<0.05). No correlation was dem-receiving rHuEpo therapy (P<0.05) and they also had a lower median creatinine than the rHuEpo recipients onstrated between Hb and T in either those receiving rHuEpo (r=−0.033, P=0.877) or not (r=0.126, P= (P<0.02). In contrast, the duration of dialysis and median creatinine values were similar in both the 0.464), although the latter group showed a negative correlation between Hb and LH (r=−0.357, P<0.05) smaller subgroups of HD patients ( Table 3 ) .
The PD subjects receiving rHuEpo had higher serum and a positive correlation between T and SHBG (r= 0.565, P<0.02).
T (P<0.05), SHBG (P<0.01), LH (P<0.01), and FSH (P<0.05) than those not receiving rHuEpo The thyroid and adrenal status of the rHuEpo and non rHuEpo recipients were similar (Table 2 ). In the (Table 4 ) , whereas these differences were not demonstrated in the HD patients. However, the HD rHuEpo rHuEpo recipients, T4 positively correlated with TSH (r=0.621, P<0.05) and LH (r=0.666, P<0.02), while recipients had a higher median E2 than the nonrecipients (P<0.05). No trend toward a hyperoestrog-TSH positively correlated with LH (r=0.609, P<0.05). These patients also demonstrated a negative enic state was present in the PD subjects receiving rHuEpo (P=0.584), but there appeared to be a trend correlation between T4 and duration of impotence (r= −0.542, P<0.05). However, the non rHuEpo recipi-towards higher T4 (P=0.083). The latter was not present in the HD rHuEpo recipients, and they had a ents showed no correlation between T4 and TSH (r= lower mean T4 than the PD rHuEpo recipients rHuEpo recipients had significantly higher serum T (P<0.01). and SHBG levels compared to a control male dialysis population matched for age, haematological status, nutrition, and duration of sexual dysfunction.
Discussion
However, free testosterone indices were similar in both groups, suggesting that the elevated serum T was secondary to elevated serum SHBG. In contrast to This study demonstrates that many male dialysis others [4, 14, 15 ] , suppression of hyperprolactinaemia patients treated with rHuEpo continue to be troubled (P=0.337) or raised LH (P=0.173), and FSH levels by sexual dysfunction and endocrine changes that are probably attributable to rHuEpo. In particular, the (P=0.157) were not demonstrated. Of the population studied 78.7% received either after stopping rHuEpo [18 ] . Our study population was different by definition as all had sexual dysfunction CAPD or CCPD, whereas previous reports have been exclusively HD subjects [4, 5, [8] [9] [10] 12, 14, 15 ] . Although before and after rHuEpo therapy, but their frequently described improved libido (without the ability to form the age, haemoglobin and nutritional status of the PD and HD patients were well matched, the HD group satisfactory penile erections) is presumably explained by increased serum T. had a longer duration of both sexual dysfunction and dialysis. Increased serum T and SHBG levels in Nevertheless it would appear this is caused by the rise in serum SHBG, which has not previously been rHuEpo recipients were only demonstrated in the PD patients, who also had higher LH and FSH levels. described. Indeed most other studies have not reported SHBG levels, although one group found no change in Although both the PD and HD groups were hyperoestrogenic, the HD subjects receiving rHuEpo had seven male HD patients after 15 weeks [8 ] and another demonstrated a decrease in seven male HD subjects increased E2 compared to the non-recipients [10], producing the trend towards increased hyperoestrogen-after partial correction of anaemia [10 ] . Our findings are from a predominantly PD population with a mean ism for rHuEpo recipients in the whole study population. As the PD group is much larger, the demonstrated age of 52.6 years, in contrast to these studies of younger HD patients (aged between 19 and 47 years); endocrine changes are consequently more robust, and it is also possible that the longer duration of dialysis furthermore our patients had a longer duration of rHuEpo therapy. Schaefer et al. also found an in the HD patients has a role in this apparent difference in response to rHuEpo (i.e. long-standing uraemia may increased free testosterone index in their HD patients
[10], but the only study that has measured serum inhibit the responses of the hypothalamo-pituitary--gonadal axis and liver to rHuEpo therapy).
free T before and after rHuEpo therapy in the male HD population demonstrated a non-significant increase in The similar haemoglobin in the rHuEpo recipients and non-recipients could be explained by greater resid-11 subjects [15] . As no difference in free testosterone indices was demonstrated, we would anticipate that ual renal function in the latter group, and indeed a lower median creatinine was demonstrated, as well as serum free T levels are unchanged in PD subjects receiving rHuEpo. a trend toward a shorter duration of dialysis. The predialysis males had similar serum T and SHBG to However, a recent study in healthy young male subjects with a left-sided varicocele demonstrated that the dialysis patients not receiving rHuEpo, which would support a contribution from greater residual acute intravenous administration of rHuEpo caused increased plasma T in the internal spermatic vein (but renal function. However, this control group is limited by being significantly older [16 ] and having a higher without change in the peripheral level ), supporting a direct role for rHuEpo in human Leydig steroidogenhaematocrit. Furthermore greater residual renal function would be expected to be associated with higher esis [13] ; this has also been shown previously in isolated adult rat Leydig cells [19 ] . Although Leydig cells from serum T [17 ] , and thus its possible presence in the rHuEpo non-recipients makes the demonstration testicular biopsies of uraemic patients complaining of sexual dysfunction appear histologically normal [17 ] , of decreased serum T in this group all the more noteworthy.
the finding of elevated LH in the presence of low or low-normal T and an inadequate T response to stimulaThe finding of a rise in serum T following rHuEpo is not original [10, 12, 18] , although other small pro-tion by human chorionic gonadotrophin [17 ] both support the presence of Leydig-cell dysfunction in spective studies have not confirmed this [4, 5, 8, 9 ] . One report, which demonstrated increased plasma T after ESRF. Therefore rHuEpo is less likely to have a direct effect upon Leydig cells in male dialysis patients. 3 months of rHuEpo administration, also found that plasma T declined to pretreatment levels three months
The non-significant differences in gonadotrophins in the HD rHuEpo recipients contrasts with the increased reports, and includes a dialysis control population that was well matched for clinical and haematological para-LH and FSH levels in the PD patients receiving rHuEpo. Changes in the kinetics and biopotency of meters. Furthermore the previously anaemic patients had received rHuEpo for a mean duration of 0.85 LH in male HD patients following rHuEpo therapy have been recently characterized, showing that the years (10 months), and it is unlikely that any significant changes in endocrine function would occur after this average concentration of bio-LH is unchanged, although there was a more than doubling of the mass time. However, the study is limited by the measurement of basal hormones alone, and further insights into the of hormone released each secretory pulse, but a simultaneous reduction in plasma half-life [10 ] . The anticip-endocrinological effects of rHuEpo would be provided by physiological or pharmacological stimulation and ated correlation of age and gonadotrophins was not present in the rHuEpo recipients, although demon-spontaneous hormone secretion studies. This would appear to be particularly indicated in the male PD strated in the other subjects, and thus it appears that rHuEpo alters, rather than corrects, the hypothalamo-population who thus far have been relatively understudied. -pituitary-gonadal axis. Similarly the correlation between T and SHBG was not present in the rHuEpo
In conclusion, a cohort of male dialysis patients has been identified who have continued to complain of recipients, again suggesting a direct effect in altering the sex hormone balance.
sexual dysfunction after correction of anaemia with rHuEpo therapy. Their sex hormone profiles show The influence of rHuEpo upon the hyperprolactinaemia of ESRF has proved the most debated topic. An increased serum T and SHBG, but similar free testosterone indices. There was no evidence of suppression early study described normalisation of PRL levels, with accompanying improved sexual function follow-of hyperprolactinaemia, but increased LH and FSH levels were demonstrated in the PD rHuEpo recipients. ing 4 months of rHuEpo therapy [4 ] . Some subsequent studies have shown no change in PRL levels [5, [8] [9] [10] , It is possible that these endocrinological changes characterize the male dialysis patient whose impotence is while others have demonstrated a suppression [14, 15] . This study did not confirm either a normalization or not corrected with rHuEpo. Those patients whose sexual difficulties did respond to rHuEpo therapy suppression of PRL levels in the rHuEpo recipients, although these patients had sexual dysfunction which would not have been referred to the renal impotence clinic and may demonstrate different endocrine was uncorrected, and the need remains for a large prospective study to definitively answer this issue. responses. Nevertheless it is clear that those male dialysis patients whose impotence problems remain following rHuEpo therapy continue to be hyperprolactinaemic.
